UHN Start-up AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases | TDC
Company to initiate Phase 2 trial with lead gene therapy, AVR‑RD‑01, based on promising initial clinical data in Fabry disease Strong investor syndicate supports multi-product portfolio with three additional gene therapies for Gaucher disease, cystinosis and Pompe disease
Largest-ever gift to a Canadian rehab hospital will support new therapies for brain-related disorders
(Toronto - December 12, 2017) With a transformational gift of $20 million to the Toronto Rehab Foundation, Walter and Maria Schroeder, along with their family, have established The Walter and Maria Schroeder Brain Institute. This donation represents the largest ever made to a rehabilitation hospital in Canada.
Stem-cell researchers solve mystery of relapse in acute myeloid leukemia
Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.
Brain research is a central mission at Krembil
Researchers disprove link between vasectomies and prostate cancer using Ontario health data
Are vasectomies safe? Some recent studies have found a link between vasectomies and the development of prostate cancer later in life. But new research using Ontario health data has challenged these studies and shown conclusively that there is no link, giving new peace of mind to those men who have u...
Medicine by Design partners with XOR and BlueRock Therapeutics to accelerate clinical and commercial programs - Medicine by Design
A technology that could increase the number of lungs available for transplantation and a stem-cell based treatment that has the potential to reverse heart failure are both a step closer to reality after winning Medicine by Design Clinical Translation and Commercialization Awards.
UHN's digital future is coming
When we think about the future of UHN, and healthcare as a whole, most of us can only begin to imagine what's possible. Digital technology will have a tremendous impact on what this looks and feels like. "UHN is on an exploratory journey of all things digital," says Dr. David Jaffray, UHN's EVP Technology & Innovation.
Canadian neuroscience leaders tap IBM Watson to speed time to discovering new drugs for Parkinson's disease
Canadian neuroscience leaders tap IBM Watson to speed time to discovering new drugs for Parkinson’s disease
Canadian neuroscience leaders tap IBM Watson to speed time to discovering new drugs for Parkinson's
Oct. 12, 2016 /CNW/ - IBM (NYSE: IBM) Watson Health today announced that the Ontario Brain Institute (OBI) and the Movement Disorders Clinic (MDC) at University Health Network (UHN) will embark on first ever Parkinson's disease research project using the recently launched IBM Watson for Drug Discovery.
CellTrak Partners with University Health Network to Commercialize Innovative Health Care Solutions
CellTrak Partners with UHN to Commercialize Innovative Health Care Solutions, and Improve Outcomes for Canadians Suffering with Chronic Disease